Prenatal Intravenous Magnesium at 30-34 Weeks’ Gestation and Neurodevelopmental Outcomes in Offspring
JAMA · 2023
DOI: 10.1001/jama.2023.12357 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA, 2023. Verfasst von Caroline A Crowther und 6 weiteren Autor:innen. Beteiligte Einrichtung: Liggins Institute, University of Auckland, Auckland, New Zealand. Hauptthemen laut MEDLINE: Cerebral Palsy, Infant Mortality, Magnesium Sulfate, Premature Birth. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Intravenous magnesium sulfate administered to pregnant individuals before birth at less than 30 weeks’ gestation reduces the risk of death and cerebral palsy in their children. The effects at later gestational ages are unclear.
Objective
To determine whether administration of magnesium sulfate at 30 to 34 weeks’ gestation reduces death or cerebral palsy at 2 years. Design, Setting, and Participants This randomized clinical trial enrolled pregnant individuals expected to deliver at 30 to 34 weeks’ gestation and was conducted at 24 Australian and New Zealand hospitals between January 2012 and April 2018.
Intervention
Intravenous magnesium sulfate (4 g) was compared with placebo. Main Outcomes and Measures The primary outcome was death (stillbirth, death of a live-born infant before hospital discharge, or death after hospital discharge before 2 years’ corrected age) or cerebral palsy (loss of motor function and abnormalities of muscle tone and power assessed by a pediatrician) at 2 years’ corrected age. There were 36 secondary outcomes that assessed the health of the pregnant individual, infant, and child.
Results
Of the 1433 pregnant individuals enrolled (mean age, 30.6 [SD, 6.6] years; 46 [3.2%] self-identified as Aboriginal or Torres Strait Islander, 237 [16.5%] as Asian, 82 [5.7%] as Māori, 61 [4.3%] as Pacific, and 966 [67.4%] as White) and their 1679 infants, 1365 (81%) offspring (691 in the magnesium group and 674 in the placebo group) were included in the primary outcome analysis. Death or cerebral palsy at 2 years’ corrected age was not significantly different between the magnesium and placebo groups (3.3% [23 of 691 children] vs 2.7% [18 of 674 children], respectively; risk difference, 0.61% [95% CI, −1.27% to 2.50%]; adjusted relative risk [RR], 1.19 [95% CI, 0.65 to 2.18]). Components of the primary outcome did not differ between groups. Neonates in the magnesium group were less likely to have respiratory distress syndrome vs the placebo group (34% [294 of 858] vs 41% [334 of 821], respectively; adjusted RR, 0.85 [95% CI, 0.76 to 0.95]) and chronic lung disease (5.6% [48 of 858] vs 8.2% [67 of 821]; adjusted RR, 0.69 [95% CI, 0.48 to 0.99]) during the birth hospitalization. No serious adverse events occurred; however, adverse events were more likely in pregnant individuals who received magnesium vs placebo (77% [531 of 690] vs 20% [136 of 667], respectively; adjusted RR, 3.76 [95% CI, 3.22 to 4.39]). Fewer pregnant individuals in the magnesium group had a cesarean delivery vs the placebo group (56% [406 of 729] vs 61% [427 of 704], respectively; adjusted RR, 0.91 [95% CI, 0.84 to 0.99]), although more in the magnesium group had a major postpartum hemorrhage (3.4% [25 of 729] vs 1.7% [12 of 704] in the placebo group; adjusted RR, 1.98 [95% CI, 1.01 to 3.91]). Conclusions and Relevance Administration of intravenous magnesium sulfate prior to preterm birth at 30 to 34 weeks’ gestation did not improve child survival free of cerebral palsy at 2 years, although the study had limited power to detect small between-group differences. Trial Registration anzctr.org.au Identifier: ACTRN12611000491965
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Liggins Institute, University of Auckland, Auckland, New Zealand.
- School of Medicine, University of Adelaide, Adelaide, Australia.
- South Australian Health and Medical Research Institute, Adelaide.
- Department of Neonatal Medicine, Women's and Children's Hospital, Adelaide, Australia.
- School of Biomedical Engineering, University of Technology Sydney, Sydney, Australia.
Zitieren
APA
Crowther, C. A., Ashwood, P., Middleton, P. F., McPhee, A., Tran, T., Harding, J. E., & MAGENTA Study Group (2023). Prenatal Intravenous Magnesium at 30-34 Weeks’ Gestation and Neurodevelopmental Outcomes in Offspring. JAMA. https://doi.org/10.1001/jama.2023.12357
Vancouver
Crowther CA, Ashwood P, Middleton PF, McPhee A, Tran T, Harding JE, et al. Prenatal Intravenous Magnesium at 30-34 Weeks’ Gestation and Neurodevelopmental Outcomes in Offspring. JAMA. 2023. doi:10.1001/jama.2023.12357
BibTeX
@article{Crowther2023,
author = {Crowther, Caroline A and Ashwood, Pat and Middleton, Philippa F and McPhee, Andrew and Tran, Thach and Harding, Jane E and MAGENTA Study Group, MAGENTA Study Group},
title = {Prenatal Intravenous Magnesium at 30-34 Weeks’ Gestation and Neurodevelopmental Outcomes in Offspring},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2023.12357}
}
EUVIMED